Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with palbociclib, and the OPERA-01 Phase 3 clinical trial in progress will be presented on
Details of the SABCS 2023 poster presentations are:
Title: | A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, advanced and/or metastatic breast cancer. |
Poster ID: | PO4-04-12 |
Session Title: | Poster Session 4 |
Date & Time: | |
Location: | Halls 2-3 |
Title: | A Phase 1b/2 study of palazestrant (OP-1250), an oral complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD), with palbociclib in ER-positive, HER2-negative, advanced or metastatic breast cancer patients. |
Presenter: | |
Poster ID: | PS15-04 |
Session Title: | Novel Nuclear Receptor Targeting Therapies |
Date & Time: | |
Location: | Stars at |
Title: | OPERA-01: A randomized, open-label, phase 3, study of palazestrant (OP-1250) vs standard-of-care treatment for ER+, HER2- advanced or metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy. |
Poster ID: | PO3-18-09 |
Session Title: | Poster Session 3 |
Date & Time: | |
Location: | Halls 2-3 |
A copy of the presentations will be made available on Olema’s website under the Science section when it is presented at the symposium. Abstracts for the posters can be found on the SABCS 2023 website here.
Company Investor Webcast and Conference Call
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, palazestrant (OP-1250), is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 3 clinical trial, and in combination with CDK4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Palazestrant has been granted FDA Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor.
Contact:
ir@olema.com
Source: Olema Oncology
2023 GlobeNewswire, Inc., source